Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1B, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SUBJECTS

Next Previous
Trial Profile

A PHASE 1B, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SUBJECTS

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemsidomide (Primary) ; Dexamethasone (Primary) ; Elranatamab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors C4 Therapeutics

Most Recent Events

  • 25 Sep 2026 Results presented in a C4 Therapeutics media release
  • 25 Sep 2026 According to a media release from C4 Therapeutics, the Safety Data Review Committee (SDRC) has determined that the 75 µg dose of cemsidomide, administered in combination with elranatamab, is safe following completion of the first Phase 1b safety cohort involving six patients. Based on these findings, the trial will proceed to a dose-escalation safety cohort evaluating cemsidomide at 100 µg, while also advancing to a dose-expansion cohort at the 75 µg dose level.
  • 11 Aug 2026 According to C4 Therapeutics media release, the company expects to provide an update on the dose escalation progress in the second half of 2026 with data from all cohorts expected in mid-2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top